Search

Your search keyword '"Chemello, Liliana"' showing total 116 results

Search Constraints

Start Over You searched for: Author "Chemello, Liliana" Remove constraint Author: "Chemello, Liliana" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
116 results on '"Chemello, Liliana"'

Search Results

1. A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort

3. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort

4. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

6. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

7. A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and Delta cohort

8. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study

10. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort

12. Epidemiological and clinical profile of HDV infected people in care in Italy: interim analysis from the ongoing PITER cohort

14. Predicting de‐novoportal vein thrombosis after HCV eradication: A long‐term competing risk analysis in the ongoing PITER cohort

15. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

17. Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohort

19. A prospective study of direct‐acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort

20. 613 Fontan associated nephropathy: does diastolic function play a role?

21. 610 Fontan associated kidney and liver disease: can we predict organ involvement with echocardiographic assessment of systolic function and atrioventricular valve insufficiency?

24. A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort

25. Liver Fibrosis and Steatosis in Alström Syndrome: A Genetic Model for Metabolic Syndrome

26. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis

28. WED-146 - Epidemiological and clinical profile of HDV infected people in care in Italy: interim analysis from the ongoing PITER cohort

30. The weight of pre-existing cofactors for liver disease progression in patients who successfully eradicated chronic hepatitis C viral infection: an interim analysis in the PITER cohort

31. Surgical management of failing Fontan circulation: results from 30 cases with 285 patient-years follow-up.

34. THU-141-Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patients

35. SAT-262-Long-term liver function outcome and related risk factors in HCV cirrhotic patients treated with direct-acting antiviral therapy: Results from the Navigatore platform in Veneto-Italy

36. THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy

37. Modelling cost-effectiveness and health gains of a 'universal' vs. 'prioritized' HCV treatment policy in a real-life cohort

38. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis

39. Liver Angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after HCV direct-acting antivirals

40. Real-Life use of Elbasvir/Grazoprevir in Adults and Elderly Patients: A Prospective Evaluation of Comedications used in the PITER Cohort

41. Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort.

42. Liver Angiopoietin‐2 Is a Key Predictor of D e N ovo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct‐Acting Antivirals

43. FRI442 - The weight of pre-existing cofactors for liver disease progression in patients who successfully eradicated chronic hepatitis C viral infection: an interim analysis in the PITER cohort

44. Sofosbuvir plus ribavirin for difficult to treat HCV-2: improved efficacy with extended treatment duration

45. Efficacy and safety of oral DAAs HCV therapy in the elderly

46. Efficacy and safety of DAA-based oral therapy i9n a large cohort of HCV patients treated in clinical practice in Italy and monitored by the NAVIGATORE web-platform

47. Incidence and pattern of 'de novo'hepatocellular carcinoma in HCV patients treated with oral DAAs

48. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network

49. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network

50. Liver Angiopoietin‐2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct‐Acting Antivirals.

Catalog

Books, media, physical & digital resources